nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolazoline—ADRA2A—type 2 diabetes mellitus	0.289	1	CbGaD
Tolazoline—Phenacemide—Nateglinide—type 2 diabetes mellitus	0.0842	0.216	CrCrCtD
Tolazoline—Amphetamine—Nateglinide—type 2 diabetes mellitus	0.0816	0.21	CrCrCtD
Tolazoline—Dextroamphetamine—Nateglinide—type 2 diabetes mellitus	0.0816	0.21	CrCrCtD
Tolazoline—Methamphetamine—Nateglinide—type 2 diabetes mellitus	0.0793	0.204	CrCrCtD
Tolazoline—ADRA2C—Bromocriptine—type 2 diabetes mellitus	0.0762	0.309	CbGbCtD
Tolazoline—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.0723	0.293	CbGbCtD
Tolazoline—L-Phenylalanine—Nateglinide—type 2 diabetes mellitus	0.0621	0.16	CrCrCtD
Tolazoline—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0503	0.204	CbGbCtD
Tolazoline—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0482	0.195	CbGbCtD
Tolazoline—Amphetamine—CARTPT—type 2 diabetes mellitus	0.00102	0.341	CrCbGaD
Tolazoline—Phenelzine—AOC3—type 2 diabetes mellitus	0.00082	0.274	CrCbGaD
Tolazoline—Naphazoline—ADRA2A—type 2 diabetes mellitus	0.000343	0.115	CrCbGaD
Tolazoline—Methamphetamine—ADRA2A—type 2 diabetes mellitus	0.000138	0.046	CrCbGaD
Tolazoline—Benzyl alcohol—CYP2E1—type 2 diabetes mellitus	0.000136	0.0455	CrCbGaD
Tolazoline—Phentermine—CYP1A2—type 2 diabetes mellitus	0.000134	0.0449	CrCbGaD
Tolazoline—Benzyl alcohol—CYP1A2—type 2 diabetes mellitus	0.00013	0.0433	CrCbGaD
Tolazoline—Phenelzine—CYP2E1—type 2 diabetes mellitus	0.000115	0.0384	CrCbGaD
Tolazoline—Benzyl alcohol—CYP3A4—type 2 diabetes mellitus	8.58e-05	0.0286	CrCbGaD
Tolazoline—Phenelzine—CYP3A4—type 2 diabetes mellitus	7.25e-05	0.0242	CrCbGaD
Tolazoline—ADRA2B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	6.25e-06	8.63e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—APOE—type 2 diabetes mellitus	6.24e-06	8.61e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—LPL—type 2 diabetes mellitus	6.23e-06	8.59e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Hemostasis—TGFB1—type 2 diabetes mellitus	6.19e-06	8.54e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—APOA1—type 2 diabetes mellitus	6.17e-06	8.51e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—GSTM1—type 2 diabetes mellitus	6.16e-06	8.5e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	6.15e-06	8.48e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—CCR5—type 2 diabetes mellitus	6.14e-06	8.47e-05	CbGpPWpGaD
Tolazoline—HRH2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.1e-06	8.41e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—ADCY5—type 2 diabetes mellitus	6.1e-06	8.41e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—GNB3—type 2 diabetes mellitus	6.09e-06	8.4e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—LPL—type 2 diabetes mellitus	6.05e-06	8.34e-05	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.04e-06	8.33e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	6.03e-06	8.32e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	6.03e-06	8.32e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—AVP—type 2 diabetes mellitus	6.01e-06	8.29e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—MMP3—type 2 diabetes mellitus	6.01e-06	8.29e-05	CbGpPWpGaD
Tolazoline—HRH2—Signaling by GPCR—IL6—type 2 diabetes mellitus	6e-06	8.28e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—C3—type 2 diabetes mellitus	6e-06	8.28e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.98e-06	8.25e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—GNB3—type 2 diabetes mellitus	5.98e-06	8.25e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.96e-06	8.22e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	5.93e-06	8.17e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—ADCY5—type 2 diabetes mellitus	5.92e-06	8.17e-05	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	5.92e-06	8.16e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—GPX1—type 2 diabetes mellitus	5.9e-06	8.14e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—AVP—type 2 diabetes mellitus	5.9e-06	8.13e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—MMP3—type 2 diabetes mellitus	5.9e-06	8.13e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.9e-06	8.13e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.87e-06	8.1e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.85e-06	8.06e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	5.84e-06	8.06e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—APOB—type 2 diabetes mellitus	5.81e-06	8.01e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.79e-06	7.98e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.79e-06	7.98e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—CD36—type 2 diabetes mellitus	5.75e-06	7.93e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—CCR5—type 2 diabetes mellitus	5.74e-06	7.91e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	5.72e-06	7.89e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.72e-06	7.88e-05	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.71e-06	7.88e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—IRS2—type 2 diabetes mellitus	5.71e-06	7.87e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—AGT—type 2 diabetes mellitus	5.7e-06	7.86e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—APOB—type 2 diabetes mellitus	5.7e-06	7.86e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.68e-06	7.83e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Hemostasis—AKT1—type 2 diabetes mellitus	5.68e-06	7.83e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—PPP2CA—type 2 diabetes mellitus	5.67e-06	7.83e-05	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.65e-06	7.79e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.61e-06	7.74e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—CALM1—type 2 diabetes mellitus	5.61e-06	7.73e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	5.61e-06	7.73e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—C3—type 2 diabetes mellitus	5.61e-06	7.73e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—APOE—type 2 diabetes mellitus	5.59e-06	7.71e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—LEP—type 2 diabetes mellitus	5.59e-06	7.71e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	5.55e-06	7.66e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—LPL—type 2 diabetes mellitus	5.55e-06	7.65e-05	CbGpPWpGaD
Tolazoline—HRH2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.54e-06	7.64e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.52e-06	7.62e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	5.48e-06	7.56e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	5.48e-06	7.56e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.46e-06	7.52e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—MTHFR—type 2 diabetes mellitus	5.45e-06	7.51e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—LPL—type 2 diabetes mellitus	5.44e-06	7.51e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—PPARG—type 2 diabetes mellitus	5.44e-06	7.5e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.43e-06	7.49e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5.43e-06	7.49e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.38e-06	7.41e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—HIF1A—type 2 diabetes mellitus	5.35e-06	7.37e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—PPARA—type 2 diabetes mellitus	5.34e-06	7.37e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—IRS2—type 2 diabetes mellitus	5.33e-06	7.36e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—INS—type 2 diabetes mellitus	5.33e-06	7.35e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5.33e-06	7.35e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—AGT—type 2 diabetes mellitus	5.33e-06	7.35e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Hemostasis—AKT1—type 2 diabetes mellitus	5.3e-06	7.31e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	5.3e-06	7.3e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.27e-06	7.28e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.27e-06	7.27e-05	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—SRC—type 2 diabetes mellitus	5.26e-06	7.26e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—CALM1—type 2 diabetes mellitus	5.24e-06	7.22e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—LEP—type 2 diabetes mellitus	5.22e-06	7.2e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—APOE—type 2 diabetes mellitus	5.22e-06	7.2e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.21e-06	7.19e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	5.2e-06	7.18e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—AGT—type 2 diabetes mellitus	5.17e-06	7.14e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.16e-06	7.12e-05	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.13e-06	7.07e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—CCR5—type 2 diabetes mellitus	5.11e-06	7.05e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	5.11e-06	7.04e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—CALM1—type 2 diabetes mellitus	5.09e-06	7.02e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—APOE—type 2 diabetes mellitus	5.07e-06	6.99e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	5.06e-06	6.97e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	5.01e-06	6.92e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—APOA1—type 2 diabetes mellitus	5.01e-06	6.91e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—C3—type 2 diabetes mellitus	4.99e-06	6.89e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.98e-06	6.87e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.95e-06	6.83e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.92e-06	6.79e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—C3—type 2 diabetes mellitus	4.9e-06	6.76e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—ALB—type 2 diabetes mellitus	4.89e-06	6.74e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—INS—type 2 diabetes mellitus	4.77e-06	6.58e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.76e-06	6.57e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.75e-06	6.55e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—AGT—type 2 diabetes mellitus	4.75e-06	6.54e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.74e-06	6.54e-05	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.71e-06	6.49e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.7e-06	6.48e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—PIK3R1—type 2 diabetes mellitus	4.68e-06	6.45e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—NOS3—type 2 diabetes mellitus	4.68e-06	6.45e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.67e-06	6.45e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.67e-06	6.44e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.66e-06	6.43e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.66e-06	6.43e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—AGT—type 2 diabetes mellitus	4.66e-06	6.42e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.66e-06	6.42e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—LEP—type 2 diabetes mellitus	4.65e-06	6.41e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—APOE—type 2 diabetes mellitus	4.65e-06	6.41e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.62e-06	6.37e-05	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.61e-06	6.36e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.61e-06	6.36e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.6e-06	6.34e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.59e-06	6.34e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.58e-06	6.31e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—APOE—type 2 diabetes mellitus	4.56e-06	6.29e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—LEP—type 2 diabetes mellitus	4.56e-06	6.29e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	4.55e-06	6.28e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.51e-06	6.22e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—INS—type 2 diabetes mellitus	4.46e-06	6.15e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	4.42e-06	6.09e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.39e-06	6.05e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.38e-06	6.05e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.38e-06	6.05e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.34e-06	5.99e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.33e-06	5.97e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	4.33e-06	5.97e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	4.33e-06	5.97e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.31e-06	5.95e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.31e-06	5.94e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	4.31e-06	5.94e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.3e-06	5.93e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.29e-06	5.92e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—PTGS2—type 2 diabetes mellitus	4.28e-06	5.9e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.25e-06	5.87e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	4.24e-06	5.85e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	4.24e-06	5.85e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.19e-06	5.78e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.19e-06	5.77e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.19e-06	5.77e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.15e-06	5.72e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.1e-06	5.65e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.07e-06	5.61e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4e-06	5.51e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—INS—type 2 diabetes mellitus	3.97e-06	5.48e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	3.97e-06	5.48e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—RELA—type 2 diabetes mellitus	3.94e-06	5.43e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.91e-06	5.39e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.91e-06	5.39e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.91e-06	5.39e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—INS—type 2 diabetes mellitus	3.9e-06	5.38e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.84e-06	5.3e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.84e-06	5.29e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.83e-06	5.29e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.82e-06	5.27e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	3.8e-06	5.24e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	3.8e-06	5.24e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.78e-06	5.22e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.77e-06	5.2e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.77e-06	5.2e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.75e-06	5.17e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—RELA—type 2 diabetes mellitus	3.68e-06	5.08e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.65e-06	5.03e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	3.62e-06	4.99e-05	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.59e-06	4.95e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.58e-06	4.94e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.56e-06	4.91e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.55e-06	4.9e-05	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—IL6—type 2 diabetes mellitus	3.55e-06	4.89e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.53e-06	4.87e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.5e-06	4.83e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.5e-06	4.83e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.49e-06	4.81e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.48e-06	4.8e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.48e-06	4.8e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	3.47e-06	4.79e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.42e-06	4.71e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.42e-06	4.71e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.36e-06	4.63e-05	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.35e-06	4.62e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.33e-06	4.59e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.32e-06	4.58e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.32e-06	4.58e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.3e-06	4.55e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—RELA—type 2 diabetes mellitus	3.28e-06	4.52e-05	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.27e-06	4.51e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.26e-06	4.49e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	3.22e-06	4.44e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.18e-06	4.38e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.18e-06	4.38e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.14e-06	4.33e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.1e-06	4.28e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	3.1e-06	4.27e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.04e-06	4.2e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.02e-06	4.16e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	2.99e-06	4.12e-05	CbGpPWpGaD
Tolazoline—HRH1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.98e-06	4.12e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.96e-06	4.08e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.94e-06	4.05e-05	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.93e-06	4.04e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.9e-06	4e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—SRC—type 2 diabetes mellitus	2.89e-06	3.99e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.88e-06	3.98e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.82e-06	3.89e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.79e-06	3.85e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.77e-06	3.82e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.76e-06	3.81e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.74e-06	3.78e-05	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.72e-06	3.75e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.71e-06	3.74e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.71e-06	3.74e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.71e-06	3.74e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.7e-06	3.72e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.68e-06	3.69e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.66e-06	3.67e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.59e-06	3.57e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.58e-06	3.55e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.55e-06	3.51e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.53e-06	3.5e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	2.53e-06	3.49e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.52e-06	3.48e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.51e-06	3.46e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.47e-06	3.41e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.46e-06	3.4e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	2.35e-06	3.24e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.3e-06	3.18e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.29e-06	3.16e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.26e-06	3.12e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.26e-06	3.11e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.22e-06	3.06e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—AKT1—type 2 diabetes mellitus	2.15e-06	2.96e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.1e-06	2.9e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	2.09e-06	2.88e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.06e-06	2.84e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—IL6—type 2 diabetes mellitus	1.95e-06	2.69e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.92e-06	2.65e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.8e-06	2.48e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	1.75e-06	2.41e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.74e-06	2.39e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.7e-06	2.35e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.6e-06	2.21e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.58e-06	2.18e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.57e-06	2.17e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.46e-06	2.01e-05	CbGpPWpGaD
